Small Molecule HGF Mimetics for Hematopoietic Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematopoietic conditions and disorders, such as thrombocytopenia and bone marrow failure, lack effective agents that can modulate hematopoietic growth factor (HGF) activity to stimulate blood cell proliferation and development, particularly in conditions exacerbated by chemotherapy, radiation, and bone marrow transplantation.
Innovation Solution
Development of compounds, specifically those of Formula VIIIaa, which act as selective HGF modulators, agonists, antagonists, or partial agonists, capable of binding to HGF receptors to enhance hematopoiesis and treat various hematological and neurological disorders by administering them before, during, or after chemotherapy, bone marrow transplantation, and for conditions like aplastic anemia and nerve injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant DNA technology is used to produce hematopoietic growth factors, then the ability to clone genes and produce factors is improved, but the complexity of production and delivery increases
Solution Approach 1:
The patent creates small molecule compounds that copy and mimic the biological activity of large protein hormones like erythropoietin. Instead of producing the actual complex protein through recombinant DNA technology, the invention uses simplified small molecule structures (Formulas I-VII with various substituents) that replicate the receptor-binding and biological effects, thereby avoiding the production complexity while maintaining the therapeutic reliability
Solution Approach 2:
The invention transforms the molecular parameters from large protein structures (30.4 kDa erythropoietin with 165 amino acids and carbohydrate portions) to small molecule structures with molecular weights typically under 1000 Da. This parameter change simplifies production, improves pharmacokinetic properties, and enables oral administration while preserving the essential biological function of stimulating hematopoietic growth factor receptors
2Ease of operation
If small molecule HGF mimetics are developed, then the ease of administration and pharmacokinetic properties are improved, but the selectivity and specificity for HGF receptors must be maintained
Solution Approach 1:
The patent applies local quality by designing specific functional groups and substitution patterns at particular positions within the small molecule structure. The formulas specify particular substituents (R1-R20, A1-A10, etc.) at defined locations that are responsible for receptor binding specificity, while other parts of the molecule provide pharmacokinetic advantages. This localized optimization allows the molecule to maintain high specificity for HGF receptors while enjoying the benefits of small molecule pharmacology
Solution Approach 2:
The small molecule compounds act as intermediaries that bridge the gap between the simplicity of small molecules and the biological activity of complex proteins. These compounds mediate the interaction with HGF receptors by mimicking the protein hormone's binding interface, enabling selective receptor activation without requiring the complex structure of the original protein, thus achieving both ease of administration and binding specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively modulate HGF activity to stimulate blood cell production, treat hematopoietic disorders, and promote nerve cell repair, offering therapeutic benefits for conditions like thrombocytopenia, aplastic anemia, and neurological diseases by enhancing hematopoiesis and neuroprotection.
Implementation Method 1
compounds with physiological effects, such as the activation of hematopoietic growth factor receptors
Data Source
AI summary
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.